Human papillomavirus type 16 E7 gene (HPV16 E7) (HPV16 E7)

The Human papillomavirus type 16 (HPV16) E7 genomic DNA locus is a critical oncogenic driver in the development of HPV-associated malignancies, including cervical and oropharyngeal cancers (NIH, 2023). This locus encodes the E7 oncoprotein, which primarily functions by binding to and promoting the degradation of the retinoblastoma protein (pRb), thereby disrupting cell cycle control and facilitating malignant transformation (PubMed, PMID: 29033145). As a therapeutic target, the E7 DNA locus is the focus of various innovative strategies, including DNA vaccines like VGX-3100 designed to elicit a robust T-cell response (Inovio Pharmaceuticals, 2024). Additionally, CRISPR/Cas9-based gene editing systems are being developed to directly inactivate the viral genome by targeting this specific locus (Nature Communications, 2017). By targeting the DNA sequence itself, these therapies seek to eliminate the source of oncogenic protein production and clear persistent viral infections. Clinical development is highly active, with several DNA-based immunotherapies undergoing trials to treat high-grade squamous intraepithelial lesions (StatPearls, 2023). Successful targeting of this locus represents a curative approach to preventing the progression of HPV-induced neoplasia.

Other names

HPV-16 E7 oncogeneHuman papillomavirus 16 E7 DNA locusHPV16 E7 geneHuman papillomavirus type 16 early protein 7 gene

Induction of antigen-specific T-cell responses against E7-expressing cells and direct enzymatic cleavage of viral DNA sequences.